A case report of refractory pulmonary adenocarcinoma
Advances in Radiotherapy & Nuclear Medicine · 2023
DOI: 10.36922/arnm.0883 ↗Kurz gefasst
Fallbericht in der Zeitschrift Advances in Radiotherapy & Nuclear Medicine, 2023. Verfasst von Haiyan Li und 2 weiteren Autor:innen. Die Arbeit wurde bisher 7-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
As one of the most common types of carcinomas, lung cancer has high incidence and mortality rates. Among the pathological types of lung cancer, pulmonary adenocarcinoma is the most prevalent. Advancements in medical treatments have contributed to improved prognosis in pulmonary adenocarcinomas. However, this case report revealed a rare refractory lung adenocarcinoma, suggesting that further research and robust management strategies are needed to improve clinical outcomes. In this regard, 18F-fluorodeoxyglucose positron emission tomography/ computed tomography plays a very important role in the comprehensive evaluation of glucose metabolic activity in lung adenocarcinoma and the progression of metastasis in distant organs.
Zitieren
APA
Li, H., Xu, C., & Lu, X. (2023). A case report of refractory pulmonary adenocarcinoma. Advances in Radiotherapy & Nuclear Medicine. https://doi.org/10.36922/arnm.0883
Vancouver
Li H, Xu C, Lu X. A case report of refractory pulmonary adenocarcinoma. Advances in Radiotherapy & Nuclear Medicine. 2023. doi:10.36922/arnm.0883
BibTeX
@article{Li2023,
author = {Li, Haiyan and Xu, Chifeng and Lu, Xia},
title = {A case report of refractory pulmonary adenocarcinoma},
journal = {Advances in Radiotherapy & Nuclear Medicine},
year = {2023},
doi = {10.36922/arnm.0883}
}
EUVIMED